Research Report

Mankind Pharma Limited

Prepared By-

ANUJ SHARMA
EQUITY RESEARCH ANALYST

About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.

- #1 Rank in Prescriptions over the last 8 yrs.

- #2 Rank by volume & #4 Rank by value in IPM

- 4 Consumer healthcare brands ranked #1 in their categories.

Business Segments

Revenue Bifurcation Segment wise (Q2FY25)

- Cardiovascular: 15%
- Anti-Infectives: 14%
- Gynaecology: 10%
- Gastro Intestinal: 10%
- Anti-Diabetic: 8%
- VMN: 8%
- Respiratory: 8%
- Urology: 5%
- Dermatology: 5%
- Pain / Analgesics: 4%
- Neuro / CNS: 2%
- Others: 11%

Revenue Break up 1HFY26

- Domestic: 86.5%
- Exports: 13.5%

Segmental Revenue H1FY26

- Pharma - 93%
- Consumer Healthcare - 7%

Synopsis of Financials

FY27: Financial performance and key drivers:

- Consolidated revenue: INR 4,031 cr (+13% YoY).
- EBITDA: INR 1,060 cr; EBITDA margin 26.3% (+250 bps YoY), driven primarily by gross margin expansion.
- PAT: INR 574 cr (+29.1% YoY); PAT margin 14.2% (+170 bps YoY), helped by higher EBITDA and lower finance costs, partly offset by higher tax rate.

Source: Company Annual Report

Stock data (as 18th September 2026)

Nifty Price	: 23,295.50
52 week High (in Rs.)	: 2,674.00
52 week Low (in Rs.)	: 1,909.70
Market Cap. (in Crore)	: 94,971.46
NSE Code	: INE634S01028

Stock data

-NIFTY-50
-Mankind Pharma Limited

Shareholding Pattern (June 2026)



-PUBLIC GROUP
-PROMOTER GROUP

Financial Summary

Particular	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Sales -	7,782	8,749	10,260	12,207	14,278
Sales Growth %	25.22%	12.44%	17.27%	18.98%	16.96%
Expenses +	5,791	6,848	7,743	9,182	10,653
Operating Profit	1,991	1,902	2,517	3,026	3,625
OPM %	26%	22%	25%	25%	25%
Net Profit +	1,453	1,310	1,942	2,011	1,938
EPS in Rs	35.78	32	47.75	48.26	46.34
Dividend Payout %	0%	0%	0%	0%	2%

Quaterly Results

Particular	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Jun-26
Sales -	3,079	3,570	3,697	3,567	3,443	4,031
YOY Sales Growth %	27.13%	24.50%	20.77%	11.52%	11.81%	12.89%
Expenses -	2,396	2,724	2,776	2,648	2,513	2,974
Material Cost %	28.43%	29.51%	28.73%	27.42%	27.84%	27.25%
Employee Cost %	23.25%	21.94%	22.32%	23.09%	21.83%	22.66%
Operating Profit	683	847	921	919	930	1,056
OPM %	22%	24%	25%	26%	27%	26%
Other Income -	249	83	94	-31	94	49
Other income normal	253.65	83.05	94.19	75.96	117.28	48.94
Interest	191	171	170	157	142	110
Depreciation	231	219	222	223	223	226
Profit before tax	511	540	624	509	659	769
Tax %	17%	18%	17%	19%	15%	25%
Net Profit +	425	445	520	414	559	574

Source: Screener

Key Ratios

Ratios	FY2026	FY2025
Debtors Turnover (no. of days)	41.77	35.45
Inventory Turnover (no. of days)	190.88	190.23
Interest Coverage Ratio (in times)	4.09	5.63
Current Ratio (in times)	1.07	1.23
Debt Equity Ratio (in times)	0.39	0.59
Operating Profit Margin (in %)	24.5	24.8
Net Profit Margin (in %)	13.4	16.3
Return on Net Worth (in %)	11.7	13.9

Source: Company Annual Report

Yearly Results

Particulars	March 2022	March 2023	March2024	March2025	March2026
Equity Capital	40	40	40	41	41
Reserves	6,115	7,395	9,323	14,291	16,259
Borrowings	873	170	207	8,511	6,312
Other Liabilities	2,080	2,080	2,313	4,808	5,143
Total Liabilities	9,108	9,686	11,883	27,652	27,755
Fixed Assets	3,588	4,251	4,545	19,005	18,620
CWIP	701	550	282	826	1,128
Investments	1,109	1,346	2,568	2,042	1,985
Other Assets	3,709	3,538	4,488	5,780	6,022
Total Assets	9,108	9,686	11,883	27,652	27,755

Source: Screener

Synopsis Quarter Results

Concall Notes - Aug-2026: Key Highlights

Q1 FY27: Financial performance and key drivers:

- Consolidated revenue: INR 4,031 cr (+13% YoY).
- EBITDA: INR 1,060 cr; EBITDA margin 26.3% (+250 bps YoY), driven primarily by gross margin expansion.
- Gross margin: 72.8% (+230 bps YoY). CFO attributed this to:
    a. price increases,
    b. mix improvement (chronic contribution +120 bps YoY incl. BSV), and
    c. a favorable base (Q1 FY26 had "inventory-related accruals… for slow and non-moving items").

- PAT: INR 574 cr (+29.1% YoY); PAT margin 14.2% (+170 bps YoY), helped by higher EBITDA and lower finance costs, partly offset by higher tax rate.
- Finance cost: INR 110 cr (down from INR 142 cr in Q4 FY26) due to repayment of an INR 1,250 cr NCD tranche in Q1 FY27.
- Effective tax rate: 25.4% vs 17.7% YoY, due to adoption of new tax regime after Sikkim plant tax exemption expiry.
- R&D spend: INR 98 cr (2.4% of sales); management reiterated FY27 guidance 2.8–3.0%, implying a ramp-up ahead.
- Working capital: Net operating working capital 52 days (vs 48 days YoY), mainly from higher inventory; management expects inventory rationalization and WC normalization by year-end.
- Cash conversion: Cash flow/EBITDA 77% vs 99% YoY, driven by higher tax, working capital, and "base effect in Q1 FY26".
- Capex: INR 198 cr (4.9% of revenue); below FY27 guidance 6–7%, implying higher spending in subsequent quarters.
- Leverage/deleveraging: Net debt INR 3,377 cr; net debt/adj. EBITDA 0.9x. Company remains on track to repay "acquisition-related debt by FY28."

Highlights

Key Financial Metrics

Financials / Margins	Growth	Capital Efficiency
4,031 *Revenue (INR Cr)*	**12.9%** *YoY Growth*	**13% / 43%** *ROCE / Adj. ROCE[1]*
1,060 / 26.3% *EBITDA (INR Cr) / Margin*	**24.7%** *YoY Growth*	**3,377** *Net Debt (INR Cr)*
574 / 14.2% *PAT (INR Cr) / Margin*	**29.1%** *YoY Growth*	**0.9x** *Net Debt / Adj. EBITDA[2]*





Source: Investor Presentation

Peer Comparison

Peer Stock Performance (2023-2026) Indexed



Source: Trading View

Peer Financial Performance

Name	CMP Rs.	P/E	Mar Cap Rs.Cr.	Div Yld %	NP Qtr Rs.Cr.	Qtr Profit Var %	Sales Qtr Rs.Cr.	Qtr Sales Var %	ROCE %
Mankind Pharma	2299.9	44.5	94965.2	0.0	574.1	29.6	4030.6	12.9	13.5
Cipla	1377.8	31.1	111302.7	0.9	785.6	-39.2	7119.3	2.3	15.5
Laurus Labs	1968.5	97.3	106360.4	0.1	362.1	125.5	2026.3	29.1	17.8
Dr Reddy's Labs	1191.7	30.8	99468.9	0.7	435.6	-68.7	8099.8	-5.5	13.0

Source: Screener

Final Outlook

MANKIND : HOLD| LTP: 2299.90

Summary
Mankind Pharma continues to show strong business momentum, supported by consistent revenue growth, a strong domestic pharmaceutical franchise and improving profitability. Q1 FY27 was particularly positive, with revenue growing 13% and PAT increasing 29.1%, while EBITDA margin improved to 26.3%. The company is also reducing debt and remains focused on deleveraging. However, higher tax rates, working-capital requirements and the relatively high valuation compared with some peers need to be monitored.

Recent Performance – Q1 FY27
Mankind Pharma delivered a strong start to FY27:

- Revenue: ₹4,031 Cr, up 13% YoY
- EBITDA: ₹1,060 Cr
- EBITDA Margin: 26.3%, improving by 250 bps YoY
- Gross Margin: 72.8%, up 230 bps YoY
- PAT: ₹574 Cr, up 29.1% YoY
- PAT Margin: 14.2%, up 170 bps YoY
- Finance Cost: reduced to ₹110 Cr from ₹142 Cr in Q4 FY26.
- R&D spending was ₹98 Cr, with management guiding for 2.8–3.0% of sales for FY27.

Mankind Pharma remains a fundamentally strong pharmaceutical company with a leading position in the Indian market, consistent revenue growth and improving operating profitability. The recent Q1 FY27 performance was encouraging, with strong EBITDA and PAT growth along with continued debt reduction.
Strong business + improving profitability + debt reduction